Inactive Instrument

Other languages Novartis CBOE EUROPE EQUITIES

Equities

0QLR

CH0012005267

End-of-day quote CBOE EUROPE EQUITIES Other stock markets
- ^EUR	-

02:00pm	Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	RE
05-31	NOVARTIS AG : UBS reiterates its Buy rating	ZD

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	08:00am
NOVARTIS AG : UBS reiterates its Buy rating	05-31
European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected	05-31
Swiss Market Index in the Green Amid US Rate Cut Optimism	05-31
NOVARTIS AG : Jefferies remains its Buy rating	05-31
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints	05-31
Novartis Says New Data Show Long-term Efficacy, Safety of Potential Urticaria Therapy	05-31
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	05-31
Novartis : Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high risk node negative disease	05-31
Novartis : essai positif dans la leucémie myéloïde chronique	05-31
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	05-31
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML	05-31
Novartis : l'efficacité du rémibrutinib pour l'urticaire -USC	05-31
Novartis' Chronic Spontaneous Urticaria Treatment Shows Long-term Efficacy in Late-stage Trial Data	05-30
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria	05-30
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria	05-30
Goldman Sachs Starts Novartis With Buy Rating, $120 Price Target	05-30
Alembic Pharmaceuticals Gets US FDA Final Nod for Sacubitril and Valsartan Tablets	05-30
NOVARTIS AG : From Sell to buy Rating by Goldman Sachs	05-30
Novartis : résultats de phase III positifs dans la C3G	05-27